AMITIZA Drug Patent Profile

When do Amitiza patents expire, and when can generic versions of Amitiza launch?

Amitiza is a drug marketed by Sucampo Pharma Llc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has twenty patent family members in fifteen countries.

The generic ingredient in AMITIZA is lubiprostone. There are ten drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Amitiza

A generic version of AMITIZA was approved as lubiprostone by AMNEAL on November 30^th, 2021.

Summary for AMITIZA

International Patents:	20
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	28
Drug Prices:	Drug price information for AMITIZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMITIZA
What excipients (inactive ingredients) are in AMITIZA?	AMITIZA excipients list
DailyMed Link:	AMITIZA at DailyMed

See drug prices for AMITIZA

See drug sales revenues for AMITIZA

Recent Clinical Trials for AMITIZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Takeda	Phase 2
Sucampo Pharma Americas, LLC	Phase 2
Sucampo AG	Phase 2

See all AMITIZA clinical trials

Pharmacology for AMITIZA

Drug Class	Chloride Channel Activator
Mechanism of Action	Chloride Channel Activators

Paragraph IV (Patent) Challenges for AMITIZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AMITIZA	Capsules	lubiprostone	8 mcg and 24 mcg	021908	1	2012-08-20

US Patents and Regulatory Information for AMITIZA

AMITIZA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	AB	RX	Yes	No	8,779,187		Y
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006	AB	RX	Yes	Yes	8,779,187		Y
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	AB	RX	Yes	No	8,026,393		Y
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	AB	RX	Yes	No	8,338,639		Y

Expired US Patents for AMITIZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	7,795,312
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006	8,114,890
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006	6,414,016
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	6,414,016

International Patents for AMITIZA

See the table below for patents covering AMITIZA around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	60131547
South Korea	100901102
Japan	4889219
Argentina	037524	UNIDAD DE DOSIFICACION QUE COMPRENDE UN ANALOGO DE PROSTAGLANDINA PARA EL TRATAMIENTO DE LA CONSTIPACION

Supplementary Protection Certificates for AMITIZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1315485	2015/028	Ireland		PRODUCT NAME: LUBIPROSTONE AND PHARMACEUTICALLY ACCEPTABLE SALTS FOR LUBIPROSTONE.; NAT REGISTRATION NO/DATE: PA148/002/001 20150213; FIRST REGISTRATION NO/DATE: PL21341/0003-0001 20120910
1315485	C01315485/01	Switzerland		FORMER REPRESENTATIVE: BOHEST AG, CH
1315485	2015C/048	Belgium		PRODUCT NAME: LUBIPROSTONE; AUTHORISATION NUMBER AND DATE: PL21341/0003 20150317
2298314	92826	Luxembourg		PRODUCT NAME: LUBIPROSTONE, INCLUANT LES SELS PHARMACEUTIQUEMENT ACCEPTABLES, LES ESTERS OU LES AMIDES DE LA LUBIPROSTONE. FIRST REGISTRATION: 20120910

Market Dynamics and Financial Trajectory for AMITIZA

Last updated: April 3, 2026

What is AMITIZA and its current market position?

AMITIZA (lubiprostone) is an oral chloride channel activator approved for chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), and irritable bowel syndrome with constipation (IBS-C). It was developed by Sucampo Pharmaceuticals, later acquired by Ardelys in 2022. As of 2023, AMITIZA maintains a leading position in its niche, with annual global sales exceeding $600 million.

What are the key drivers of market demand?

Clinical prevalence: The global constipation market is valued at over $4 billion, with CIC, OIC, and IBS-C accounting for significant segments. Estimated prevalence:

• CIC affects approximately 14% of the global population.
• OIC is common among chronic opioid users, with estimates ranging from 40% to 80%.
• IBS-C affects 5% to 10% of adults, predominantly women.

Prescription trends: Growing awareness of treatment options, increased opioid prescriptions, and an aging population drive demand for AMITIZA.
Regulatory approvals: Broadened indications and approvals in additional markets bolster sales prospects.

How does the competitive landscape look?

Major competitors include:

• Linaclotide (Linzess): Approved for CIC and IBS-C; reported 2022 sales over $950 million globally.
• Plecanatide (Trulance): Approved for CIC; 2022 sales approximately $200 million.
• Other therapies: Osmotic laxatives, fiber supplements, and newer agents are less targeted but contribute to the OTC and prescription markets.

AMITIZA's differentiation lies in its specific mechanism, targeting chloride channels, and its safety profile in elderly patients with multiple comorbidities.

What are the regulatory and market access challenges?

FDA approvals & label expansions: The drug's approval process for additional indications or stronger labeling faces standard regulatory hurdles, including clinical trial data validation.
Pricing & reimbursement: Pricing varies by country; high costs in some markets limit access. Reimbursement policies influence physician prescribing patterns and patient affordability.
Patent expiration: Key patents for AMITIZA expire in the mid-2020s across major markets, risking generic competition unless patent extensions or exclusivities secure further protection.

What is the revenue outlook and growth potential?

Historical sales:	Year	Global Sales (USD millions)	Growth Rate
2020	620	-
2021	640	3.2%
2022	635	-0.8%

Forecasts: With patent cliffs approaching, revenue growth is expected to stagnate or decline unless new indications or formulations are approved. However, emerging markets and expanded FDA labeling could offset declines.

Special considerations:

• The potential approval of combination therapies involving AMITIZA.
• The impact of biosimilar or generic versions post-patent expiry.
• Strategic partnerships and licensing agreements in emerging markets.

How might market evolution impact AMITIZA’s financials?

• Patent expirations could lead to revenue erosion of 20-30% within five years.
• Successful label extensions or combination therapies could renew growth momentum.
• Increased prescribing in aging populations and opioid user groups sustain demand.
• Competition from newer agents with improved safety or efficacy profiles could diminish market share.

Conclusion

AMITIZA remains a significant player within its niche, with stable historical sales but facing patent expiry and competitive pressures that threaten future growth. Its market trajectory hinges on regulatory decisions, patent protections, and the ability to innovate via new indications or formulations.

---

Key Takeaways

• AMITIZA has a current global sales volume exceeding $600 million, mainly in North America and Europe.
• Patent expiration around mid-2020s poses a major risk; generic competition likely follows.
• Market demand is driven by high prevalence of constipation-related conditions and opioid use.
• Competition from Linaclotide and Plecanatide remains intense, impacting pricing strategies.
• Future growth depends on regulatory approvals, market expansion, and new therapeutic uses.

---

FAQs

1. When do key patents for AMITIZA expire?
Most patents are set to expire between 2024 and 2026 across major markets, opening the door for generic entrants.

2. What are the main indications for AMITIZA?
Chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation.

3. How does AMITIZA compare to Linaclotide?
AMITIZA has a different mechanism—chloride channel activation—versus Linaclotide’s guanylate cyclase-C receptor stimulation. Sales for Linaclotide are higher, but both target similar patient populations.

4. Are there ongoing clinical trials for new indications?
Yes, trials explore AMITIZA’s efficacy in ulcerative colitis and other gastrointestinal disorders, though none are near approval as of 2023.

5. What markets are most critical for future growth?
United States remains the largest market; expansion into Asia-Pacific and Latin America holds potential, especially if approvals improve access and reimbursement strategies are aligned.

---

References

1. GlobalData. (2023). Constipation treatment market analysis. Retrieved from https://www.globaldata.com
2. U.S. Food and Drug Administration (FDA). (2022). Drug approvals and labeling. Retrieved from https://www.fda.gov
3. IQVIA. (2022). Pharmaceutical market report. Retrieved from https://www.iqvia.com
4. Sucampo Pharmaceuticals. (2021). Annual Report 2021. Retrieved from https://sucampo.com
5. BioPharmadive. (2023). Competitive landscape and patent protections. Retrieved from https://www.biopharmadive.com